Online inquiry

IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2731MR)

This product GTTS-WQ2731MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2731MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3066MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ9009MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ3204MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ2058MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ11416MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ11489MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ11826MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ11745MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW